ApoEdp Peptide Eye Drops for Diabetic Retinopathy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetic retinopathy are invasive and often ineffective, with significant side effects, and there is a need for non-invasive methods that target the underlying mechanisms of diabetic retinopathy, such as endothelial cell damage and extracellular matrix degradation.
Innovation Solution
A non-invasive topical eye drop treatment using a peptide that mimics human apolipoprotein E (apoEdp), which inhibits the expression of heparanase and matrix metalloproteinases, thereby reducing inflammation and angiogenesis in the retina.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If laser photocoagulation and anti-angiogenic therapy are used to treat diabetic retinopathy, then angiogenic regression and reduction of macular edema are achieved, but significant side effects occur and many patients remain unresponsive
Solution Approach 1:
The patent uses heparanase inhibitors as intermediary substances that block the pathological action of heparanase on the extracellular matrix. Instead of directly attacking angiogenic vessels (as in laser photocoagulation) or using broad-spectrum anti-angiogenic agents, the invention introduces a specific molecular mediator that interrupts the disease mechanism at the level of ECM degradation, thereby achieving therapeutic effect with reduced side effects
Solution Approach 2:
The patent changes the therapeutic parameter from direct vascular intervention (laser energy, anti-VEGF agents) to enzymatic inhibition (heparanase inhibitors). This parameter change targets the root cause of BRB dysfunction - excessive ECM degradation - rather than treating downstream effects, improving treatment reliability while reducing harmful side effects associated with conventional therapies
2Reliability
If heparanase inhibitors are used to treat diabetic retinopathy, then angiogenesis and inflammation are reduced, but thrombin-induced platelet aggregation is inhibited and anti-coagulant activities are prolonged
Solution Approach 1:
The patent applies local quality by delivering heparanase inhibitors specifically to the retinal tissue through topical ocular administration. This localized delivery ensures high concentration of the drug at the disease site (retina) while minimizing systemic exposure, thereby reducing the harmful effects of platelet aggregation inhibition and prolonged anti-coagulant activities that would occur with systemic administration
Solution Approach 2:
The patent introduces topical ocular administration as an intermediary delivery route that bridges the gap between effective drug dosing and minimal systemic side effects. This delivery mechanism acts as a mediator that confines the drug action primarily to the ocular region, reducing the likelihood of systemic thrombotic and bleeding complications
3Reliability
If current anti-angiogenic therapies are used, then vascular leakage is reduced, but the underlying mechanisms of diabetic retinopathy such as endothelial cell damage and extracellular matrix degradation are not addressed
Solution Approach 1:
The patent applies preliminary action by targeting heparanase inhibition before significant vascular damage occurs. By blocking ECM degradation at its source, the therapy prevents the cascade of events leading to BRB dysfunction, neovascularization, and macular edema. This proactive approach addresses underlying mechanisms rather than merely responding to established pathology, making the treatment more versatile and potentially preventive
Solution Approach 2:
The patent extracts and isolates the specific pathological mechanism of heparanase-mediated ECM degradation from the complex pathology of diabetic retinopathy. By focusing therapy on this single key mechanism rather than treating all manifestations simultaneously, the invention achieves both symptom control and mechanism targeting, improving adaptability while maintaining effectiveness
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The apoEdp peptide effectively crosses the cornea to reach the retina, inhibiting key enzymes and proteins involved in diabetic retinopathy, reducing vascular leakage and retinal damage, and providing a statistically significant reduction in retinal pathology.
Implementation Method 1
The apoEdp peptide effectively crosses the cornea to reach the retina
Implementation Method 2
inhibiting key enzymes and proteins involved in diabetic retinopathy
Implementation Method 3
inhibiting the expression of heparanase and matrix metalloproteinases
Data Source
AI summary
Compositions useful for treatment of retinal pathologies, including diabetic retinopathy, and methods of making and using said compositions, are provided.